A critical review found moderate evidence supporting THC:CBD combinations for MS-related spasticity and pain, but evidence for other MS symptoms remains limited.
MS patients and their clinicians, medical cannabis researchers, and neurologists.
Nabiximols approved in 25+ countries for MS spasticity
What the researchers found
The review found the strongest evidence for nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) in reducing spasticity and neuropathic pain in MS patients. Evidence for effects on tremor, bladder dysfunction, and sleep was less consistent.
Why it matters
Multiple sclerosis affects millions worldwide, and spasticity is one of its most debilitating symptoms. This review consolidates what is known about cannabinoid treatments to help clarify where the evidence is strongest.
The numbers in context
Nabiximols (Sativex) is approved in over 25 countries for MS spasticity; clinical trials typically showed 20-30% improvement in spasticity scores.
How the study worked
Critical narrative review synthesizing clinical trial data, observational studies, and regulatory submissions for cannabinoid-based treatments in multiple sclerosis.
What this study cannot tell us
Narrative review format (not systematic); heterogeneity in how MS symptoms are measured across studies; many trials had small sample sizes.
How to read the evidence
Moderate: synthesizes clinical trial data but uses narrative review format rather than systematic methodology.
When this study was published
Published 2016.
The bigger picture
Nabiximols represents one of the most successful translations of cannabinoid science into approved medicine. Its targeted use for MS spasticity shows how specific cannabinoid formulations may work best for specific symptoms rather than as broad treatments.
Questions still open
- Could different THC:CBD ratios be more effective for specific MS symptoms? What are the long-term effects of sustained cannabinoid use in MS patients?
Common questions
Which MS symptoms respond best to cannabinoid treatment?
Is Sativex widely available?
Read the original research
A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.
Molecules (Basel, Switzerland), 25(21)
Citation
Jones, Éamon; Vlachou, Styliani. (2020). A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.. Molecules (Basel, Switzerland), 25(21). https://doi.org/10.3390/molecules25214930
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk